Skip to main content
Projected 2023 Cost Reduction From Tumor Necrosis Factor α Inhibitor Biosimilars in Dermatology: A National Medicare Analysis
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Projected 2023 Cost Reduction From Tumor Necrosis Factor α Inhibitor Biosimilars in Dermatology: A National Medicare Analysis
User login
Username
Password
Reset your password
Concept
Lead
score
Biologic Therapy
1
1
Biosimilars
0
0.89
Medicare
0
0.41
Specialty
Lead
score
Dermatology
1
1
Pharmacist
0
1
Edit Tags